Madrid

• A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af … Ended
  2023-509137-39-00 5 2015-11-06 Stage IB (T ≥ 4 cm), II and IIIA NSCLC
• A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic … Ended
  2024-514269-20-00 5 2015-05-06 Metastatic Non-Small Cell Lung Cancer
• A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can … Ended
  2024-517856-36-00 5 2015-03-09 Completely resected primary stage IB (≥ 4cm), II and IIIA non-small ce
• A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended
  2023-504034-22-00 5 2014-12-18 Chronic Lymphocytic Leukemia (CLL)
• A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended
  2023-504761-23-00 5 2014-11-19 Advanced or metastatic renal cell carcinoma
• BEACON: A randomised phase IIb trial of BEvACizumab added to Temozolomide ± IrinOtecan for children with refractory/relapsed Neuroblastoma Ended
  2024-518931-12-00 4 2014-05-15 Neuroblastoma
• A Long-Term, Open-Label, Study for Treatment of JIA Ended
  2023-509651-14-00 10 2013-04-03 Juvenile Idiopathic Arthritis (JIA)
• Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO) Ended
  2024-512730-15-00 4 2012-09-14 Systemic Lupus Erythematosus
• A Phase II Study of Dasatinib in Children and Adolescents with Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolera … Ended
  2024-510784-36-00 9 2009-04-27 Children and Adolescents with Newly Diagnosed Chronic Phase CML or wit
• EQU-001 as an Add-On Drug for People with Focal Seizures while on Medication Ended
  2022-500302-18-00 4 Epilepsy
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of ABBV-916 in … Ended
  2022-500691-59-00 4 Alzheimer's disease (AD)
• A trial to learn if andexanet alfa is safe and works to limit bleeding in people who take factor 10a inhibitors and urgently need surgery Ended
  2022-501353-37-00 5 Reversal of anticoagulation effect in patients on a FXa inhibitor (api
• A Phase 1/2 Study of DCC-3116 in Patients With MAPK Pathway Mutant Solid Tumors Ended
  2022-501474-19-00 7 Non-Small Cell Lung Cancer
• A Phase 1/2 Study of the Safety, Pharmacokinetics and Anti-Tumor Activity of the Oral KIT Inhibitor THE-630 in Patients with Advanced Gastro … Ended
  2022-502087-21-00 7 Gastrointestinal Stromal Tumors (GIST)
• Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Ended
  2022-502233-25-00 5 Schizophrenia
• Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy Ended
  2022-502316-36-00 11 Symptomatic Obstructive Hypertrophic Cardiomyopathy
• A study to test a medicine (fitusiran) for preventing bleeds in people with severe hemophilia who previously received preventive treatment w … Ended
  2022-502414-84-00 3 Hemophilia A
• A Phase 1 study to evaluate IK-930 in subjects with advanced solid tumors Ended
  2022-502622-40-00 1 Advanced Solid Tumors
• C4971006: A Study to Learn About the Effects of 2 Study Medicines (Maplirpacept [PF-07901801] and Glofitamab) When Given Together in People … Ended
  2022-502822-41-00 9 Relapsed/Refractory Diffuse Large B Cell Lymphoma
• A Phase 2 Study of BMS-986315 and Nivolumab in Combination with Chemotherapy in Participants with First-line Stage IV or Recurrent NSCLC Ended
  2022-503007-22-00 4 Non-small Cell Lung Cancer
• A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 (SAR445710) in Subjects With Metast … Ended
  2022-503080-15-00 1 Cancer
• Study of Obeldesivir in Children and Adolescents With COVID-19 Ended
  2023-503282-27-00 10 COVID-19
• Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY) Ended
  2023-503457-35-00 9 Epithelial tumours
• OXU-001 compared to Intravitreal Ozurdex for the Treatment of Diabetic Macular Edema Ended
  2023-503496-17-00 4 Diabetic Macular Edema (DME)

Showing 3,481–3,504 of 3,550 trials